Diligence memo · auto-generated · as of July 2, 2026
Biolimitless Centers of Excellence, Inc.
Biolimitless Centers of Excellence, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Biolimitless Centers of Excellence, Inc. operates in Other Health Care, based in DOVER.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Biolimitless Centers of Excellence, Inc. has raised $202K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $20M on 2024-09-16.
Most recent recorded round closed around 2024-10-23.
Valuation (modeled)modeled
Provath models Biolimitless Centers of Excellence, Inc. at approximately $1.2M (range $475K–$2.0M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.01× the median modeled value of Series B Other Health Care companies in 2022–2024 (91 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 1 months.
Last raise 20 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 10% of Other Health Care peers (5377 compared).
Modeled value ranks above 7% of those peers.
Closest niche peers: Code Biotherapeutics, Inc., Candesant Biomedical, Inc., Artis Holdings, LLC, GIO Blood Ltd, Clarapath, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.